143 Alternative Candida vaccine candidates: rAls3p-N vs. rAls1p-N  by Spellberg, B.J. et al.
Internationa( Journa( of Infectious Diseases (2006) 1 O($1) 80-81 
ELSEVIER http://intL etsevierheatth.com/journa[s/ijid 
Abstracts 
Other Miscellaneous Infections in the Immunocompromisecl Host 
143 
Alternative Candida Vaccine Candidates: 
rAIs3p-N vs. rAIslp-N 
B.J. Spettberg*, A.S. Ibrahim, V. Avanesian, Y. Fu, 
S. Fitter, C. Meyers, Q.T. Phan, J.E. Edwards Jr.. 
Los Angeles Biomedical Research Institute and the 
Division o[ In[ectious Diseases at Harbor-UCLA 
Medical Center, Torrance, CA, USA 
Background: We have identified a vaccine candi- 
date protein, the recombinant N-terminus of Atslp 
(rAtslp-N), that provides protection against dis- 
seminated candidiasis in mice. Atslp is a member 
of a famity of retated Ats proteins, of which Atslp 
and Ats3p bind to the broadest array of host con- 
stituents. 
Objectives: To determine if vaccination of rAts3p-N 
provides comparabte protection against invasive 
Candida infection as compared to rAtslp-N. 
Methods: To determine the potentiat utitity of 
rAts3p-N as a vaccine candidate, we compared the 
immunogenicity of rAtslp-N vs. rAts3p-N in mice. 
We atso compared the efficacies of these proteins 
in systemic and mucosat modets of invasive candi- 
dat infection. 
Results: rAts3p-N resutted in more broadty cross- 
reactive antibody responses than did rAtslp-N. 
rAts3p-N mediated simitar efficacy compared to 
rAtslp-N in a murine mode[ disseminated candidia- 
sis. However, rAts3p-N, but not rAtslp-N, mediated 
protection in a murine mode[ of candidat vaginitis. 
Conclusions: The rAts3p-N vaccine is a promising 
candidate for further devetopment for the preven- 
tion of invasive candidat infections in humans. 
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Molecular Analysis of Human Parechovirus 
Infections 
E Ghazi 1., A. Akbar Gorzin 1, B. DaNrmanesh 2, 
G. Stanway 3. 1Department o[ Microbiology, School 
o[ Medicine, Iran University o[ Medical Sciences; 
2Department o[ Biochemistry, University o[ 
Azzahra, Tehran, Iran, 3Department o[ Molecular 
Virology, University o[ Essex, Colchester, UK 
Background: Human parechovirus type 1 (HPEV1) 
is a common pathogen that usuatty causes mitd 
disease, typicatty in chitdren during the first year of 
rife. This virus was isotated in 1956 from chitdren 
suffering from diarrhea and it is stiff mostty de- 
tected in gastroenteritis and respiratory infections 
but other manifestation have atso been reported. 
HPEV1 betongs to the human parechovirus species 
of the recentty recognized parechovirus genus 
of picornaviridae. Human Picornaviruses have a 
singte-stranded RNA genome of positive potarity. 
Virus reptication invotves the synthesis of a targe 
potyprotein, which is cteaved by virus specific pro- 
teases to give the finat functionat proteins. These 
proteases are important in virat rife cycte and are 
a target for antivirat drugs. One of the eartiest 
steps in picornavirus potyprotein processing occurs 
at either the N-terminat (as in entero- and rhi- 
noviruses) or C-terminat (as in aphtho- and car- 
diovirus) boundary of the 2A protein. Activity of 
this protein differs markedty between these two 
groups. Recent sequence anatysis uggests that hu- 
man parechovirus 1 (HPEV1) is distinct from other 
Picornaviruses and tacks the motifs betieved to 
be invotved in the protease function of 2A. To 
study processing directty, constructs containing the 
HPEV1 2A encoding regions have been transcribed 
and transtated using an in vitro system. 
Results: The resutts showed that the region en- 
coded by genomic positions of 2700-4200 (part of 
VP1, 2A, and 2B and part of 2C) is not capabte 
of autocatatytic processing. Since no processing of 
potypeptide containing 2A was observed, then the 
3C region was added to the cDNA constructs to test 
whether processing has occurred. Expression of this 
